Imaging primary prostate cancer with 11C-Choline PET/CT: relation to tumour stage, Gleason score and biomarkers of biologic aggressiveness

Open access

Imaging primary prostate cancer with 11C-Choline PET/CT: relation to tumour stage, Gleason score and biomarkers of biologic aggressiveness

Background. As a significant overlap of 11C-Choline standardized uptake value (SUV) between prostate cancer and benign prostate hyperplasia (BPH) tissue, controversy exists regarding the clinical value of 11C-Choline PET/CT scan in primary prostate cancer. In this study, the SUVmax of the prostate lesions and the pelvic muscles were measured and their ratios (SUVmax-P/M ratio) were calculated. Then we evaluated whether the tracer 11C-Choline uptake, quantified as SUVmax-P/M ratio, correlated with tumour stage, Gleason score, and expression levels of several biomarkers of aggressiveness.

Methods. Twenty-six patients with primary prostate cancer underwent 11C-Choline PET/CT. Tumour specimens from these patients were graded histopathologically, and immunnohistochemistry for Ki-67, CD31, androgen receptor (AR), Her-2/neu, Bcl-2, and PTEN were performed.

Results. Both SUVmax and SUVmax-P/M ratio showed no significant difference between patients with tumour stage II and III, but significantly elevated in patients with tumour stage IV. SUVmax-P/M ratio was also significantly higher in lesions with Gleason score of 4+3 or higher versus less than or equal to 3+4. SUVmax-P/M ratio was found significantly correlated with expression levels of Ki-67 and CD31. In addition, a higher SUVmax-P/M ratio was demonstrated in Her-2/neu positive subgroup than negative subgroup. At the same time, Gleason score and expression levels of these biomarkers showed no significant association with SUVmax.

Conclusions. Using the parameter SUVmax-P/M ratio, 11C-Choline PET/CT may be a valuable non-invasive imaging technology in the diagnosis of primary prostate cancer.

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010; 60: 277-300.

Brawley OW, Ankerst DP, Thompson IM. Screening prostate cancer. CA Cancer Clin 2009; 59: 264-73.

Albersen PC. A challenge to contemporary management of prostate cancer. Nat Clin Pract Urol 2009; 6: 12-3.

Avazpour I, Roslan RE, Bayat P, Saripan MI, Nordin AJ, Abdullah RSAR. Segmenting CT images of bronchogenic carcinoma with bone metastases using PET intensity markers approach. Radiol Oncol 2009; 43: 180-6.

Rojnik M, Jevnikar Z, Mirkovic B, Janes D, Zidar N, Kikelj D, et al. Cathepsin H indirectly regulates morphogenetic protein-4 (BMP-4) in various human cell lines. Radiol Oncol 2011; 45: 259-66.

Ben-Haim S, Ell P. 18f-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med 2009; 50: 88-99.

Farsad M, Schiavina R, Franceschelli A, Sanguedolce F, Castellucci P, Bertaccini A, et al. Positron emission tomography in imaging and staging prostate cancer. Cancer Biomarkers 2008; 4: 277-84.

Westerterp M, Sloof GW, Hoekstra OS, Ten Kate FJ, Meijer GA, Reitsma JB, et al. 18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. J Cancer Res Clin Oncol 2008; 134: 227-36.

Gu J, Yamamoto H, Fukunaga H, Danno K, Takemasa I, Ikeda M, et al. Correlation of Glut-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer. Dig Dis Sci 2006; 51: 2198-205.

Ueda S, Kondoh N, Tsuda H, Yamamoto S, Asakawa H, Fukatsu K, et al. Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer. BMC Cancer 2008; 8: 384.

Nakamura H, Hirata T, Kitamura H, Nishikawa J. Correlation of the standardized uptake value in FDG-PET with the expression level of cell-cycle-related molecular biomarkers in resected non-small cell lung cancers. Ann Thorac Cardiovasc Surg 2009; 15: 304-10.

Backes H, Ullrick R, Neumaier B, Kracht L, Wienhard K, Hacobs AH. Noninvasive quantification of tumour proliferation in patients with high-grade glioma. Eur J Nucl Mol Imaging 2009; 36: 1960-7.

Kawai N, Zhen HN, Miyake K, Yamamaoto Y, Nishiyama Y, Tamiya T. Prognostic value of pretreatment 18F-FDG PET in patients with primary central system lymphoma: SUV-based assessment. J Neuroncol 2010; 100: 225-32.

American Joint Committee on Cancer. Prostate. In: Greene FL, Page DL, Fleming ID, editors. AJCC Cancer staging manual. 6th edition. New York: Springer; 2002. p. 309-16.

Li X, Liu Q, Wang M, Jin X, Liu Q, Yao S, et al. C-11 choline PET/CT imaging for differenting malignant from benign prostate lesions. Clin Nucl Med 2008; 10: 671-6.

Shukla-Dave A, Hricak H, Ishill N, Moskowitz CS, Drobnjak M, Reuter VE, et al. Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles. Clin Cancer Res 2009; 15: 3842-9.

Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, et al. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005; 113: 619-28.

Veltri RW, Isharwal S, Miller MC, Epstein JI, Mangold LA, Humphreys E, et al. Long term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis. Prostate 2008; 68: 1806-15.

Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial fingdings of PET with 2-deoxy-2[F-18]fluoro-D-glucose. Radiology 1996; 199: 751-6.

Hodolic M. Role of F-choline PET/CT in evaluation of patients with prostate carcinoma. Radiol Oncol 2011; 45: 17-21.

Hara T. 11C-choline and 2-deoxy-2-[18F]fluoro-D-glucose in tumor imaging with positron emission tomography. Mol Imaging Biol 2002; 4: 267-73.

Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C, et al. [11C] Choline uptake with PET/CT for initial diagnosis of prostate cancer: relation to PSA levels, tumour stage, and antiandrogenic therapy. Eur J Nucl Med Mol Imaging 2008; 35: 1065-73.

Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F] fluorodeoxyglucose-positron emission tomography. J Urol 2003; 169: 1337-40.

Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, et al. Detection of lymphy-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007; 52: 423-9.

Tuncel M, Souvatzoglou M, Herrmann K, Stollfuss J, Schuster T, Weirich G, et al. [11C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nucl Med Bio 2008; 35: 689-95.

Reske SN, Blumstein NM, Glatting G. [11C]Choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J NuclMol Imaing 2008; 35: 9-17.

Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, et al. Detection and localization of prostate cancer: correlation of 11C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005; 46: 1642-9.

Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998; 6: 990-5.

Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000; 27: 1415-9.

de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol 2002; 42: 18-23.

Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F, Kocot D, et al. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 2006; 47: 1642-9.

Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P, et al. Kinetics of [(11)C] choline uptake in prostate cancer: a PET study. Eur J Nucl Mol Imaging 2004; 31: 317-24.

Yamaguchi T, Lee J, Uemura H, Sasaki T, Takahashi N, Oka T, et al. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Mol Imaging 2005; 32: 724-8.

Breeuwsma AJ, Pruim J, Jongen MM, Suurmeijer AJ, Vaalburg W, Nijman RJ, et al. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging 2005; 32: 668-73.

Piert M, Park H, Khan A, Siddiqui J, Hussain H, Chenevert T, et al. Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques. J Nucl Med 2009; 50: 1585-93.

Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555-65.

Sogani PC, Israel A, Lieberman PH, Lesser ML, Whitmore WF Jr. Gleason grading of prostate cancer: a predictor of survival. Urology 1985; 25: 223-7.

Kumar-Sinha C, Chinnaiyan AM. Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer. Urology 2003; 62(Suppl 1): 19-35.

Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005; 41: 858-87.

Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, et al. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 2009; 100: 888-93.

Erbersdobler A, Isbarn H, Dix K, Steiner I, Schlomm T, Mirlacher M, et al. Prognostic value of microvessel density in prostate cancer: a tissue microarray study. World J Urol 2010; 28: 687-92.

Silberman MA, Partin AW, Veltri RW, Epstein JI. Tumor angiogenesisi correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 1997; 79: 772-9.

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.

Calvo BF, Levine AM, Marcos M, Collins QF, Iacocca MV, Caskey LS, et al. Human epidermal receptor-2 expression in prostate cancer. Clin Cancer Res 2003; 9: 1087-97.

Savinainen KJ, Saramäki OR, Linja MJ, Bratt O, Tammela TL, Isola JJ, et al. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol 2002; 160: 339-45.

Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000; 92: 1918-25.

Edwards J, Traynor P, Munro AF, Pirret CF, Dunne B, Bartlett JM. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. ClinCancer Res 2006; 12: 123-30.

Minner S, Jessen B, Stiedenroth L, Burandt E, Köllermann J, Mirlacher M, et al. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res 2010; 16: 1553-60.

Radiology and Oncology

The Journal of Association of Radiology and Oncology

Journal Information

IMPACT FACTOR 2018: 1,846
5-year IMPACT FACTOR: 1,923

CiteScore 2018: 1.94

SCImago Journal Rank (SJR) 2018: 0.651
Source Normalized Impact per Paper (SNIP) 2018: 0.867


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 297 236 45
PDF Downloads 73 60 12